{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T22:12:22Z","timestamp":1648937542686},"reference-count":11,"publisher":"EDP Sciences","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1051\/medsci\/20102611911","type":"journal-article","created":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T14:04:33Z","timestamp":1298988273000},"page":"911-914","source":"Crossref","is-referenced-by-count":1,"title":["Leuc\u00e9mie my\u00e9lo\u00efde chronique et th\u00e9rapeutiques cibl\u00e9es"],"prefix":"10.1051","volume":"26","author":[{"given":"Gabriel","family":"Etienne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2010,11,15]]},"reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Saglio G, Kim DW, Issaragrisil S,et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.N Engl J Med2010 ; 362 : 2251-9.","DOI":"10.1056\/NEJMoa0912614"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Shah NP, Hocchaus A, et al.Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med2010 ; 362 : 2260-70.","DOI":"10.1056\/NEJMoa1002315"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med2003 ; 348 : 994-1004.","DOI":"10.1056\/NEJMoa022457"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F,et al.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.Leukemia2009 ; 23 : 1054-61.","DOI":"10.1038\/leu.2009.38"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Giles F, Wunderle L,et al.Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.N Engl J Med2006 ; 354 : 2542-51.","DOI":"10.1056\/NEJMoa055104"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Talpaz M, Shah NP, Kantarjian H,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.N Engl J Med2006 ; 354 : 2531-41.","DOI":"10.1056\/NEJMoa055229"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Rosti G, Palandri F, Castagnetti F,et al.Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia.Blood2009 ; 114 : 4933-8.","DOI":"10.1182\/blood-2009-07-232595"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Cortes JE, Jones D, O\u2019Brien S,et al.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.J Clin Oncol2010 ; 28 : 392-7.","DOI":"10.1200\/JCO.2009.25.4896"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Cortes JE, Jones D, O\u2019Brien S,et al.Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.J Clin Oncol2010 ; 28 : 398-404.","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"R10","unstructured":"Turhan A. Imatinib mesylate: a major breakthrough in the treatment of chronic myelogenous leukemia.Med Sci (Paris)2003 ; 19 : 667-8"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Roche-Lestienne C, Mahon FX, Preudhomme C. Origin of resistance to Imatinib mesylate: lessons learned from this experience.Med Sci (Paris)2004 ; 20 : 1125-30","DOI":"10.1051\/medsci\/200420121125"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/20102611911\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T18:23:41Z","timestamp":1560018221000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/20102611911"}},"subtitle":["Bient\u00f4t l\u2019embarras du choix ?"],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":11,"journal-issue":{"issue":"11"},"alternative-id":["medsci20102611p911"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/20102611911","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}